Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Prostate. 2011 Nov 29;72(10):1140–1149. doi: 10.1002/pros.22463

Fig. 4. Heregulin-α activates HER3 and stimulates sPLA2-IIa expression in prostate cancer cells.

Fig. 4

LNCaP, LNCaP-AI, and LAPC4 cells were starved in 1% stripped medium for 24 hours. The cells were then treated with various concentrations of Heregulin-α for 24 hours (A). The cells were also treated with Lapatinib (10 uM) and Bortezomib (5 uM) without or with Heregulin-α (50 ng/ml) for 24 hours (B-D). The cell extracts were prepared and subjected to western blot analysis for sPLA2-IIa, HER2, P-HER2, HER3, and P-HER3.